Femring

Femring is a brand name of estradiol, approved by the FDA in the following formulation(s):

FEMRING (estradiol acetate - insert, extended release; vaginal)

• 
  Manufacturer: GALEN LTD
  
  Approval date: March 20, 2003
  
  Strength(s): EQ 0.05MG BASE/24HR, EQ 0.1MG BASE/24HR ^[RLD]

Has a generic version of Femring been approved?

No. There is currently no therapeutically equivalent version of Femring available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Femring. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Intravaginal drug delivery devices for the administration of 17.beta.-oestradiol precursors
  Patent 5,855,906
  Issued: January 5, 1999
  Inventor(s): McClay; Allen
  Assignee(s): Galen (Chemicals) Limited
  The invention relates to an intravaginal drug delivery device for administration to a female mammal of certain 17.beta.-oestradiol precursors at a substantially constant rate for a period of at least three weeks. The 17.beta.-oestradiol precursor is a 17.beta.-oestradiol moiety in which the, or each, hydroxyl group of the 17.beta.-oestradiol moiety is blocked by a blocking group, which blocking group is readily removed from the 17.beta.-oestradiol in vivo. The 17.beta.-oestradiol precursor must have either a solubility in liquid silicone of not less than 0.1 mg/100 ml or a standard k value of not less than 0.1 .mu.g/day/mm. The 17.beta.-oestradiol precursor must also have a solubility in distilled water of not less than 1 .mu.g/100 ml.
  
  Patent expiration dates:
  
  
  • December 19, 2015
    
    ✓ 
    Patent use: METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
  
  

See also...

• Femring Ring Consumer Information (Wolters Kluwer)
• Femring Consumer Information (Cerner Multum)
• Estradiol Consumer Information (Drugs.com)
• Estradiol Consumer Information (Wolters Kluwer)
• Estradiol Acetate Consumer Information (Wolters Kluwer)
• Estradiol Cypionate Consumer Information (Wolters Kluwer)
• Estradiol Gel Consumer Information (Wolters Kluwer)
• Estradiol Gel Packets Consumer Information (Wolters Kluwer)
• Estradiol Patch Consumer Information (Wolters Kluwer)
• Estradiol Ring Consumer Information (Wolters Kluwer)
• Estradiol Spray Consumer Information (Wolters Kluwer)
• Estradiol Valerate Consumer Information (Wolters Kluwer)
• Estradiol Weekly Patch Consumer Information (Wolters Kluwer)
• Estring Ring Consumer Information (Wolters Kluwer)
• Estradiol injection Consumer Information (Cerner Multum)
• Estradiol oral Consumer Information (Cerner Multum)
• Estradiol topical for use on skin Consumer Information (Cerner Multum)
• Estradiol transdermal Consumer Information (Cerner Multum)
• Estradiol vaginal Consumer Information (Cerner Multum)
• Estradiol AHFS DI Monographs (ASHP)